A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with
cocaine dependence. This is a DB, placebo-controlled, parallel group design study where
subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week
follow-up.

Inclusion Criteria:

Must have a DSM-4 criteria for cocaine dependence; be seeking treatment for cocaine
dependence; have the ability to understand and provide written informed consent; females
of child-bearing potential using proper method of birth control.

Exclusion Criteria:

Additional criteria available during screening at the site.